Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2020

View Archived Issues

Toxicity, infectivity separate issues for prion protein

Bio-Path begins phase I study of BP-1002 in advanced lymphoid malignancies

Synthetic lethal approach for some breast, brain cancers

CuraSen begins phase I study of CST-2032 for neurodegenerative disease

Stem cell-derived CC exosomes improve MI recovery in pigs

Vaxess partners with Medigen Vaccine on combined COVID-19 and influenza vaccine

Synthekine closes series A financing to advance its innovative pipeline

Proniras receives NIDA grant to pursue development of tezampanel for opioid withdrawal

Institute of Organic Chemistry and Biochemistry of the ASCR divulges hSTING agonists

Researchers discloses EFdA prodrugs for HIV infections

Autobahn Therapeutics synthesizes new TR-beta agonists

Moderna and Vertex enter new collaboration to develop gene-editing therapies for CF

FDA approves pilot study of hCT-MSCs therapy to treat COVID-19-related MIS-C

Eisai presents compounds for cognitive disorders

New CDK2/cyclin E inhibitors patented by Incyte

Phase III EMPACTA trial of Actemra in COVID-19-associated pneumonia meets primary endpoint

BG-P-TAT, novel dual targeting agent with promising efficacy in models of neuroblastoma

Novel mutation in the PRKCG gene tied to spinocerebellar ataxia 14

Sorrento cleared by FDA to conduct phase I study of COVI-GUARD for COVID-19

Animal model shows potential of fluvoxamine for non-motor Parkinson's disease symptoms

Junshi and Wigen collaborate on four of Wigen's cancer drug candidates

FDA clears IND for phase I study of MOR-210 in advanced solid tumors

INT-230-6 studied in combination with Yervoy for advanced cancers in phase II

New phase II trial investigates fostamatinib for treatment of hospitalized COVID-19 patients

Elicio collaborates with Moffitt to characterize AMP-CD19 with CAR T cells

Celltrion cleared in Korea to begin phase II/III study of CT-P59 for COVID-19

Papyrus and Oxford Biomedica sign research collaboration agreement for CAR-T cell development

HSG and Prilenia partner on phase III study of pridopidine in Huntington's disease

NanoViricides nominates NV-CoV-1-R as clinical drug candidate for COVID-19

Covimro shown to disrupt viral membrane and dislodge S spike proteins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...